Compare CDMOs with ADC manufacturing capabilities for bioconjugation, cytotoxic payload synthesis, and integrated antibody-drug conjugate production.
Antibody-drug conjugate (ADC) manufacturing combines three distinct manufacturing disciplines: monoclonal antibody production (biologics), cytotoxic payload and linker synthesis (high-potency small molecule chemistry), and bioconjugation (attaching the payload to the antibody). Few CDMOs can handle all three under one roof, making ADC CDMO selection particularly complex.
Bioconjugation is the differentiating step. The process of attaching cytotoxic payloads to antibodies via chemical linkers requires: controlled reaction conditions in contained environments (the payloads are potent), precise drug-to-antibody ratio (DAR) control, conjugation chemistry expertise (cysteine, lysine, site-specific), and analytical methods for DAR characterization. CDMOs with established conjugation platforms save significant development time.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.